Alzamend Neuro (ALZN) Net Equity Issued and Repurchased (2021 - 2025)

Alzamend Neuro has disclosed Net Equity Issued and Repurchased across 4 years of filings, most recently posting $4.0 million for Q3 2025.

• In Q3 2025, Net Equity Issued and Repurchased rose 105.49% year-over-year to $4.0 million; the TTM figure through Jul 2025 stood at $9.8 million (up 36.25% YoY), while the FY2026 annual figure was $4.0 million, down 47.84% from the prior year.
• Net Equity Issued and Repurchased came in at $4.0 million for Q3 2025 at Alzamend Neuro, down from $5.9 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $5.9 million in Q2 2025 to a low of -$789420.0 in Q4 2024.
• Average Net Equity Issued and Repurchased over 4 years is $2.1 million, with a median of $2.0 million recorded in 2024.
• The largest YoY upside for Net Equity Issued and Repurchased was 2076.17% in 2025 against a maximum downside of 28.59% in 2025.
• Over 4 years, Net Equity Issued and Repurchased stood at $2.0 million in 2021, then soared by 100.0% to $4.0 million in 2022, then plunged by 119.74% to -$789420.0 in 2024, then soared by 611.13% to $4.0 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $4.0 million in Q3 2025, $5.9 million in Q2 2025, and $688700.0 in Q1 2025.